Product Description
Mechanisms of Action: Vitamin K Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Turku University Hospital
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-000390-22 |
Tahdistin-Varfariini | P4 |
Completed |
Unknown |
2025-01-08 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |